• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    W

    Wockhardt Inc.

    企业
    105论文总数
    1,438引用总数

    Wockhardt Ltd. is a global pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. More than half of its revenue comes from Europe. It has market presence in Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. The company employs over 8,600 people globally. Wockhardt Hospitals is a subsidiary of the Wockhardt Group.

    论文量&引用量时间轴

    机构学者

    论文(105)

    年份
    起
    –
    止
    排序
    1P-1209. Efficacy of Β-Lactam Enhancer Based Zidebactam-Cefepime Combination (WCK 5222) Versus Meropenem in Adults with Complicated Urinary Tract Infection (cuti) or Acute Pyelonephritis (AP) in a Global, Randomized, Double-blind, Phase 3 Trial
    Pencho Genov, Boris Mladenov, Donatas Slaitas, Mario Gonzalez, Pratikshit Mahajan,Haihui Huang, Denise Sharp, Alena Jandourek, Lily Llorens, David Friedland, Piotr Iwanowski, Ranjeet Gutte,

    The combination of β-lactam enhancer zidebactam and cefepime (ZID-FEP) is in development for the treatment of diverse infections caused by a wide range of MDR/XDR Gram-negative bacteria including MBL-producers. In a registration-enabling Phase 3 study (ENHANCE), efficacy and safety of ZID-FEP was compared against meropenem in adults with cUTI or AP.Clinical cure, microbiological eradication and overall success rates at test-of-cure visit in mMITT population This Phase 3, randomized, double-blind, active-controlled and non-inferiority trial was conducted at 44 global sites across U.S., EU, India, Mexico, and China, enrolling hospitalized adults (≥18 years old) with a clinical diagnosis of cUTI or AP ± concurrent bacteremia. Eligible patients were randomized 2:1 to receive ZID-FEP 1+ 2 g (1 h infusion) or meropenem 1 g (0.5 h infusion) for 7 to 10 days with dosage adjustments based on renal function. The primary efficacy outcome (FDA & EMA endpoint) was the proportion of patients in the Microbiological Modified Intent-To-Treat (mMITT) population who achieved overall success (clinical cure combined with microbiological eradication) at the test-of-cure (TOC) visit (Day 17±2). The non-inferiority margin was -15.0% and a pre-specified test for superiority for the primary endpoint was performed in the expanded-mMITT (e-mMITT) population following confirmation of non-inferiority (NCT04979806). Of the 529 patients randomized and treated (352 in ZID-FEP and 177 in meropenem arms), 417 included in the mMITT population (281 in ZID-FEP and 136 in meropenem). Patients > 65 years represented 62% of the mMITT population and bacteremia was present in 6.5% of patients. The overall success rate at TOC was 89.0% in the ZID-FEP group versus 68.4% in the meropenem group; treatment difference [ZID-FEP versus meropenem], 20.6%; 95% CI, 12.3 to 29.5) (Table 1). ZID-FEP was statistically superior to meropenem for the primary endpoint at the TOC in e-mMITT. Treatment difference for all analyzed sub-groups, which include cUTI versus AP, older adults, renal-insufficiency, obese patients and cefepime-resistant uropathogens were consistent with the overall study results. ZID-FEP demonstrated statistical superiority over meropenem in the overall success rates and results were consistent regardless of patient or pathogen characteristics. All Authors: No reported disclosures

    2026Open Forum Infectious Diseases(2026)
    引用
    AI阅读
    加入学术空间
    2Nafithromycin in CABP: Promise and Precaution—authors’ Reply
    Himanshu Pophale, Monica Gupta,Hariharan Periasamy,Balaji Veeraraghavan,Sachin Bhagwat
    2025The Lancet Regional Health - Southeast Asia(2025)
    引用
    AI阅读
    加入学术空间
    3Book Review Article
    Conway McGrath
    2025Journal of Voice(2025)
    引用
    AI阅读
    加入学术空间
    4Abstract TP196: Ischemic Stroke with Large Vessel Occlusion and Systemic Acidosis: Associations with Functional Outcomes and Mortality
    Alexander Andreev, Stephanie Vu,Michael Young,Amine Awad, Ryan Barrette, Nicole Cesanek, Ayesha Hossain, Daniel Forsman,Rohan Arora,Vasileios-Arsenios Lioutas,Robert Regenhardt

    Introduction: Systemic acidosis is common in critical conditions, including severe myocardial infarction, renal and liver injuries, and traumatic brain injury. However, the potential connection between ischemic stroke involving large vessel occlusion (LVO) and acidosis has not been extensively explored. With this study we aimed to assess the prevalence of respiratory and metabolic acidosis in ischemic stroke with LVO and their potential links to functional outcomes and mortality. Methods: Retrospective single center cohort of patients with ischemic stroke and LVO status post endovascular thrombectomy. Univariate logistic regression was used to examine the relationship between acidosis on admission and (1) hospital mortality and (2) 90-day modified Rankin Scale (mRS) dichotomized as unfavorable (>3) vs favorable (≤3). In addition, we investigated association with acidosis and symptomatic ICH. Metabolic acidosis was defined by the presence of one of the following: Serum bicarbonate <22 mEq/L, lactic acid >2 mmol/L or pH <7.35. Respiratory acidosis was defined by pCO2 >45 mmHg. Results: There was a total of 346 patients, average age was 68.5 (±15) years, 169 (49%) were females. 168 (49%) patients were acidotic on admission, 4 (1%) had respiratory acidosis, 7 (2%) had mixed acidosis and the remaining 157 (45%) had metabolic acidosis. There was no statistically significant association between systemic acidosis with either hospital mortality (p=0.31]) or 90-day favorable functional outcome (p=0.23]). There was no association between acidosis with symptomatic ICH (p=0.47). Conclusion: In our retrospective cohort study, we observed that approximately half of the patients with stroke and LVO had systemic acidosis. Unlike other critical neurological conditions like traumatic brain injury, we did not identify a substantial correlation between systemic acidosis and either mortality or the functional outcome at the 90-day mark. Given the high prevalence of acidosis in patients with LVO, larger multi-center studies are needed to further investigate its association with the outcomes and mortality.

    2024Stroke(2024)
    引用
    AI阅读
    加入学术空间
    5Assessment of Water Use Efficiency and Fertilizer Use Efficiency of Solar-Powered Aeroponic System
    RR Nigadi, N Ramalingannanavar,N Kumari, SM Bhagwat, G Rawat, GG Kadam, MY Khadatare, PK Keskar, DN Jagtap

    Global food consumption of the world's expanding population is predicted to increase significantly in the next decades. However, as the world's natural resource base (land, water, and air) is put under greater demand to raise food production, all of the main resources for modern agriculture are becoming less available. Increased food production can be achieved by expanding crop fields and improving cultivation. The hydroponic system is one of today's most advanced crop production methods. A hydroponic system's basic components include nutrient film technique (NFT), deep water culture (DWC), wick hydroponic, flood and drain system, drip hydroponic, and aeroponics. In this study, the solar-powered aeroponic system was compared to the conventional method of cultivating lettuce in terms of water and fertilizer efficiency. Lettuce crop production in aeroponic (5.0 kg m-2) and traditional systems (1.5 kg m-2). The water and fertilizer use efficiency of the aeroponic system and traditional approach have been determined to be 67.0 kg m-3 and 43.8%, respectively, and 6.1 kg m-3 and 25.3%.

    2024International Journal of Research in Agronomy(2024)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 105 篇论文

    合作机构(99)

    伊利诺伊大学香槟分校合作论文 3
    West Bengal University of Health Sciences合作论文 2
    Assemblée Nationale de France合作论文 2
    巴黎第一大学合作论文 2
    Institut d'Économie Industrielle合作论文 2
    Ipsen Inc.合作论文 2
    Water Authority of Jordan合作论文 2
    Freshfields Bruckhaus Deringer合作论文 2
    迈阿密大学合作论文 2
    Christian Medical College & Hospital合作论文 2

    机构统计